Item 7.01. Regulation FD Disclosure.

On March 24, 2021, Krystal Biotech, Inc. (the "Company") issued a press release announcing the launch of Jeune, Inc., a gene-based aesthetics company, and the initial safety data from the ongoing Phase 1 trial of KB301 for aesthetic indications. The Company will present more detailed data as an e-Poster talk at the Society of Investigative Dermatology (SID) Annual Meeting, which will be held as a virtual event, at 2:30pm EST on May 5, 2021. A copy of the Poster that will accompany the talk will be available at the Company's website located at www.krystalbio.com/select-scientific-publications.

The Company also announced the appointment of Dr. Bhushan Hardas M.D., MBA, who will join the Company on March 29, 2021 as president of Jeune, Inc.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

This information in this Item 7.01 of this Current Report on Form 8-K shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing.

Item 9.01 Financial Statements and Exhibits.




(d)  Exhibits.



Exhibit
  No.       Description

99.1          Press Release, dated March 24, 2021

104         Cover Page Interactive Data File (embedded within the Inline XBRL
            document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses